CN105777852A - Deflazacort synthetic method - Google Patents
Deflazacort synthetic method Download PDFInfo
- Publication number
- CN105777852A CN105777852A CN201410799032.2A CN201410799032A CN105777852A CN 105777852 A CN105777852 A CN 105777852A CN 201410799032 A CN201410799032 A CN 201410799032A CN 105777852 A CN105777852 A CN 105777852A
- Authority
- CN
- China
- Prior art keywords
- deflazacort
- synthetic method
- chakete
- ground
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 title claims description 42
- 229960001145 deflazacort Drugs 0.000 title claims description 41
- 238000010189 synthetic method Methods 0.000 title claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 239000011734 sodium Substances 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000009413 insulation Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- WFJRIDQGVSJLLH-UHFFFAOYSA-N methyl n-aminocarbamate Chemical compound COC(=O)NN WFJRIDQGVSJLLH-UHFFFAOYSA-N 0.000 claims description 10
- 230000035484 reaction time Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 238000007098 aminolysis reaction Methods 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000027932 Collagen disease Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- LHNVKVKZPHUYQO-UHFFFAOYSA-N epoxy progesterone Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CC3OC3(C(=O)C)C1(C)CC2 LHNVKVKZPHUYQO-UHFFFAOYSA-N 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 230000009033 hematopoietic malignancy Effects 0.000 claims description 3
- 230000002607 hemopoietic effect Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 2
- -1 potassium boron hydrogen Chemical class 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000007599 discharging Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- XLKNMWIXNFVJRR-UHFFFAOYSA-N boron potassium Chemical compound [B].[K] XLKNMWIXNFVJRR-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a deflazacort synthetic method, and deflazacort can be synthesized from epoxy progesterone as a starting material by dehydrogenation, oxidation, protection, ammonolysis for ring opening, ring closing, reduction, hydrolysis deprotection, loading of iodine and displacement reaction. A process route is simplified, production control points are optimized, the method is energy-saving and consumption-reducing, production efficiency is greatly improved, and the product overall yield can reach more than 68%. Production cost is saved, product market competition power is strong, and the method has great economic benefits and social benefits.
Description
Technical field
The invention belongs to pharmaceutical synthesis field, more particularly to the synthetic method of a kind of deflazacort.
Background technology
Deflazacort, general medicine name: DEFLAZACORT, another name: Azacort, Lantadin, Deflan, Calcort, Oxazacort, DL-485-IT, L-5458, chemical structural formula: molecular formula: C25H31NO6, molecular weight: 441.52.1985, Italy's Initial Public Offering.Aeroseb-Dex, has the effect such as antiinflammatory, antiallergic increase gluconeogenesis for third generation glucocorticoid.It functions as 10 ~ 20 times of prednisolone, 40 times of hydrocortisone.For treating former and secondary hypocortisolism, rheumatism collagenosis, dermatosis, allergic disease, ophthalmic diseases, fulminant and disseminata phthisis, hemopoietic system illness, ulcerative colitis, idiopathic nephrotic syndrome, the disease such as Hematopoietic Malignancies.
The existing synthesis route of deflazacort is shown in Fig. 1:
This technique walks biofermentation through the first, the second liang, then again through 11 hydroxyl oxidizes, and 21 carbonyl-protections, then epoxy addition again, then closed loop, carbonyl reduction, then through deprotection, obtain target product, total synthetic route totally 10 step finally by upper iodization.Process line is tediously long, and middle separation process is loaded down with trivial details, and the production cycle is longer, and production efficiency is comparatively low, and three waste discharge is also more, and total recovery is only about 40%.
Summary of the invention
It is desirable to provide the deflazacort synthetic method that a kind of synthetic route is simple, production efficiency improves, production cost is saved.
For achieving the above object, one deflazacort synthetic method of the present invention, its specific embodiments is:
The synthetic method of a kind of deflazacort of the present invention; it is characterized in that; with epoxy Progesterone for initiation material, through dehydrogenation, oxidation, upper protection, aminolysis open loop, closed loop, ring is former, be hydrolyzed deprotection, upper iodine, displacement reaction synthesize deflazacort, and synthetic route of the present invention is shown in Fig. 2.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that in deflazacort preparation process midbody compound ground Na Chakete methyl hydrazinocarboxylate (compound 5) with ground Na Chakete (compound 6) synthesis.
It is characterized in that, the reaction temperature of ground Na Chakete methyl hydrazinocarboxylate aminolysis ring-opening reaction is 32-35 DEG C, and the insulation reaction time is 24 hours.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that preparation ground Na Chakete methyl hydrazinocarboxylate post processing regulated value PH=6-7.
The synthetic method of a kind of deflazacort of the present invention, it is characterized in that in the process of preparation ground Na Chakete methyl hydrazinocarboxylate, after adding acetic anhydride, temperature control 30-35 DEG C, the insulation reaction time is 4-5 hour, after dropping sodium carbonate liquor, in closed loop procedure, temperature control is to 50-60 DEG C, and the insulation reaction time is 2-3 hour.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that in ground Na Chakete preparation process, after adding potassium boron hydrogen, reduction reaction controls temperature at 0 ± 1 DEG C, 5 hours insulation reaction time.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that in ground Na Chakete preparation process, after reduction reaction, reaction system regulates pH=6-7.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that in ground Na Chakete preparation process, after adding formaldehyde, deprotection reaction control
Temperature 30-40 DEG C, the insulation reaction time is 8-10 hour.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that the solvent that synthetic route is used is one or more in absolute methanol, magnesium chloride hexahydrate, sodium borohydride, glacial acetic acid, water, hydrochloric acid, formaldehyde, sodium hydroxide, chloroform, methanol, ethyl acetate.
The synthetic method of a kind of deflazacort of the present invention, it is characterised in that absolute methanol moisture content≤0.5%, concentration of hydrochloric acid 20-30%, sodium hydroxide 3W water dissolution.
The synthetic method of a kind of deflazacort of the present invention, deflazacort prepared by this technique is mainly used in treatment former and secondary hypocortisolism, rheumatism collagenosis, dermatosis, allergic disease, ophthalmic diseases, fulminant and disseminata phthisis, hemopoietic system illness, ulcerative colitis, idiopathic nephrotic syndrome, Hematopoietic Malignancies.
The method have the benefit that
Synthetic route of the present invention is on the basis of former conventional processing routes; single step reaction discharging is merged in two step biofermentation adjustment; open loop and closed loop are adjusted to single step reaction discharging; carbonyl reduction and deprotection are adjusted to single step reaction discharging; original 10 step reactions are made to become 7 steps reaction dischargings through optimizing production control point; so that reaction circuit simplifies, shorten the production cycle, thus improve production efficiency.In addition initiation material of the present invention is easy to get, and solvent is conventional solvent, and process energy consumption is low, greatly reduces production cost, improves product market competitive power.Total yield of products can reach more than 68%.Great market development economic benefit and social benefit.
Accompanying drawing illustrates:
Fig. 1: existing synthesis route figure；
Fig. 2: synthesis route figure of the present invention.
Detailed description of the invention
Example below, only for further illustrating the present invention, does not limit the present invention in any form.
Embodiment 1:
Synthetic route of the present invention is shown in Fig. 2.
The present invention, with epoxy Progesterone (compound 1) for initiation material, protects to obtain compound 4 on dehydrogenation, oxidation, carbonyl, and compound 4 is former through aminolysis open loop, closed loop, ring, hydrolysis deprotection, upper iodine, displacement reaction synthesis deflazacort.
Embodiment 2:
The preparation of deflazacort intermediate ground Na Chakete methyl hydrazinocarboxylate (compound 5):
1. DMF200ml puts into clean reaction bulb, and stirring is lower adds 100g compound 4, temperature of charge 30-35 DEG C, the incomplete molten state of material.
2. close other valve, open ammonia valve, insulation reaction 24 hours at temperature control 32-35 DEG C, after feed liquid is dissolved substantially, close ammonia valve, sampling is TLC until reacting completely, and as reaction is incomplete, extends the response time.
3. reaction is finished, and slightly lowers the temperature, and is slowly added into about 150ml glacial acetic acid, temperature control about 30 DEG C, regulates reactant liquor pH=5-6.
4. in feed liquid, add 150ml acetic anhydride, temperature control 30-35 DEG C insulation reaction 4-5 hour, if reaction is not exclusively, then add a small amount of acetic anhydride to reacting completely.
5. reaction is finished, drip 10% sodium carbonate liquor 4000ml, (rate of addition need to be controlled in case slug), dropping is finished, and feed liquid is warming up to 50-60 DEG C, insulated and stirred 2-3 hour, then being cooled to room temperature, sucking filtration, filter cake 500ml washing dries, discharging, in about 80 DEG C drying, obtains ground Na Chakete methyl hydrazinocarboxylate weight 220.3g.HPLC98.8%.
Embodiment 2
The preparation of deflazacort intermediate ground Na Chakete (compound 6):
1. 500ml absolute methanol puts into clean reaction bulb, and stirring is lower adds 100g compound 5 to entirely molten.
2. being slowly uniformly added into potassium boron hydrogen 10g under stirring, control temperature at 0 ± 1 DEG C, insulation reaction 5 hours, TLC detects to reacting completely.
3. reaction is complete, is slowly added into a small amount of acetic acid, temperature control less than 10 DEG C, regulates PH=6-7, and heating in water bath concentration methanol, add water 500ml in reactor, and reactant liquor is dropped to room temperature.
4. slowly dropping 30%100ml hydrochloric acid, material temperature is less than 50 DEG C, after material is entirely molten.Adding formaldehyde 100ml, temperature control 30-40 DEG C insulation reaction 8-10 hour in feed liquid, TLC detection reaction is to reacting completely.
5. cooling, slowly drips about 50ml, liquid caustic soda, adjusts reactant liquor PH=6-7. in dropping process in reactant liquor
6. reaction bulb system adds 500ml dichloromethane extraction, separates organic layer, water layer 200ml × 2 dichloromethane extraction twice, merge organic layer.
7. water-bath negative pressure concentration of organic layers, to dry, adds 100ml ethyl acetate, repeats above operation.The freezing crystallize of stirring, filters, washes cake, and discharging, in about 80 DEG C drying, obtains compound deflazacort weight 82.6g.HPLC98.5%.
Claims (10)
1. the synthetic method of a deflazacort; the method is with epoxy Progesterone for initiation material; protection on dehydrogenation, oxidation, carbonyl, aminolysis open loop, closed loop, ring are former, hydrolysis deprotection, upper iodine, displacement reaction synthesis deflazacort, it is characterised in that the synthesis of ground Na Chakete methyl hydrazinocarboxylate and ground Na Chakete.
2. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that in ground Na Chakete methyl hydrazinocarboxylate preparation process, the reaction temperature of aminolysis ring-opening reaction is 32-35 DEG C, and the insulation reaction time is 24 hours.
3. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that in ground Na Chakete methyl hydrazinocarboxylate preparation process, regulates pH=6-7 after aminolysis.
4. the synthetic method of a kind of deflazacort according to claim 1, it is characterized in that, in process prepared by ground Na Chakete methyl hydrazinocarboxylate, temperature control 30-35 DEG C after addition acetic anhydride, the insulation reaction time is 4-5 hour, after dropping sodium carbonate liquor, in closed loop procedure, temperature control is to 50-60 DEG C, and the insulation reaction time is 2-3 hour.
5. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that in ground Na Chakete preparation process, after adding potassium boron hydrogen, reduction reaction controls temperature at 0 ± 1 DEG C, 5 hours insulation reaction time.
6. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that in ground Na Chakete preparation process, after reduction reaction, reaction system regulates pH=6-7.
7. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that in ground Na Chakete preparation process, adds deprotection reaction temperature control 30-40 DEG C after formaldehyde, and the insulation reaction time is 8-10 hour.
8. the synthetic method of a kind of deflazacort according to claim 1, it is characterised in that the solvent that synthetic route is used is one or more in absolute methanol, magnesium chloride hexahydrate, sodium borohydride, glacial acetic acid, water, hydrochloric acid, formaldehyde, sodium hydroxide, chloroform, methanol, ethyl acetate.
9. the synthetic method of a kind of deflazacort according to claim 8, it is characterised in that absolute methanol moisture content≤0.5%, concentration of hydrochloric acid 20-30%, sodium hydroxide 3W water dissolution.
10. the synthetic method of a kind of deflazacort according to claim 1-9, deflazacort prepared by this technique is mainly used in treatment former and secondary hypocortisolism, rheumatism collagenosis, dermatosis, allergic disease, ophthalmic diseases, fulminant and disseminata phthisis, hemopoietic system illness, ulcerative colitis, idiopathic nephrotic syndrome, Hematopoietic Malignancies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410799032.2A CN105777852A (en) | 2014-12-22 | 2014-12-22 | Deflazacort synthetic method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410799032.2A CN105777852A (en) | 2014-12-22 | 2014-12-22 | Deflazacort synthetic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105777852A true CN105777852A (en) | 2016-07-20 |
Family
ID=56384963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410799032.2A Pending CN105777852A (en) | 2014-12-22 | 2014-12-22 | Deflazacort synthetic method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105777852A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459549A (en) * | 2017-08-24 | 2017-12-12 | 岳阳环宇药业有限公司 | A kind of deflazacort fast reaction technique and production system |
| CN115850360A (en) * | 2022-12-16 | 2023-03-28 | 湖南新合新生物医药有限公司 | Preparation method of deflazacort intermediate |
-
2014
- 2014-12-22 CN CN201410799032.2A patent/CN105777852A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107459549A (en) * | 2017-08-24 | 2017-12-12 | 岳阳环宇药业有限公司 | A kind of deflazacort fast reaction technique and production system |
| CN107459549B (en) * | 2017-08-24 | 2018-08-21 | 岳阳环宇药业有限公司 | A kind of deflazacort fast reaction technique and production system |
| CN115850360A (en) * | 2022-12-16 | 2023-03-28 | 湖南新合新生物医药有限公司 | Preparation method of deflazacort intermediate |
| CN115850360B (en) * | 2022-12-16 | 2025-03-14 | 湖南新合新生物医药有限公司 | Preparation method of deflazacort intermediate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105111205B (en) | A kind of preparation method of Pa Boxini | |
| CN103980263B (en) | The synthesis technique of canagliflozin | |
| CN105348045A (en) | Method for synthesizing pentafluorophenol by using continuous flow reaction | |
| CN103980336A (en) | New fulvestrant synthesis method | |
| CN105777852A (en) | Deflazacort synthetic method | |
| CN103664923B (en) | The preparation method of Nifuratel | |
| CN105585539B (en) | The method of one pot process cefotaxime side chain acetoacetic ester | |
| CN104086619B (en) | The preparation method of danazol | |
| CN101234957A (en) | A kind of synthetic method of 2,7-dimethyl-2,4,6-octatriene-1,8-dialdehyde | |
| CN102321016A (en) | Synthesis method of 5-bromo-2-methyl 4-hydroxypyridinecarboxylate | |
| CN105152947A (en) | Preparation method of 2-amino-3,5-dibromobenzaldehyde | |
| CN105524042A (en) | Method for preparing trelagliptin | |
| CN104725460B (en) | Male steroid-4-alkene-6 ��, the preparation method of 19-ring oxygen-3,17-diketone | |
| CN103059096A (en) | Synthesis method of deflazacort intermediate with [17a,16a-d] oxazoline structure | |
| CN103087136A (en) | Novel process for preparing progesterone | |
| CN103923003A (en) | Preparation method of 4-bromomethylquinoline-2(H)-ketone | |
| CN102659638B (en) | Synthetic method of leonurine | |
| CN104945459B (en) | A kind of method preparing finasteride intermediate | |
| WO2018121051A1 (en) | Preparation method for methyl 3-cyano-4-isopropoxybenzoate | |
| CN104529924B (en) | The preparation method of 5-cyclopropyl-4-[2-methylthio group-4-(trifluoromethyl) benzoyl] isoxzzole | |
| CN104945458B (en) | A kind of synthetic method of progesterone | |
| CN105061327B (en) | A kind of synthetic method of sulfamethoxyplridazine | |
| CN103848772A (en) | Preparation method of important intermediate of Silodosin | |
| CN104098540B (en) | A kind of method preparing Zaltoprofen | |
| CN106749098A (en) | A kind of friendly process for preparing dioxopromethazine hydrochloride as oxidant with oxygen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |